Table of Content

1. 1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. U.S. CAR-T Cell Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)
6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
6.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
6.2.4. By Treatment Type (Single Treatment, Combination Treatment)
6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
6.2.7. By Region (Northeast Region, Midwest Region, South Region, West Region)
6.2.8. By Company (2022)
6.3. Market Map
6.3.1. By Product Type
6.3.2. By Tumor Type
6.3.3. By Indication
6.3.4. By Treatment Type
6.3.5. By Targeted Antigen
6.3.6. By End User
6.3.7. By Region
7. North-East CAR-T Cell Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Tumor Type
7.2.3. By Indication
7.2.4. By Treatment Type
7.2.5. By Targeted Antigen
7.2.6. By End User
8. Mid-West CAR-T Cell Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Tumor Type
8.2.3. By Indication
8.2.4. By Treatment Type
8.2.5. By Targeted Antigen
8.2.6. By End User
9. South CAR-T Cell Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Tumor Type
9.2.3. By Indication
9.2.4. By Treatment Type
9.2.5. By Targeted Antigen
9.2.6. By End User
10. West CAR-T Cell Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Tumor Type
10.2.3. By Indication
10.2.4. By Treatment Type
10.2.5. By Targeted Antigen
10.2.6. By End User
11. Market Dynamics
11.1. Drivers
11.1.1. Rising Prevalence of Cancer
11.1.2. Recent Developments
11.2. Challenges
11.3. Commercialization of CAR-T Cell Therapy
11.4. Lack of Skilled Personnels
11.5. Higher cost of the therapy
12. Market Trends & Developments
13. Competitive Landscape
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (In Case of Listed Companies)
13.5. Key Personnel
13.5.1. Gilead Sciences, Inc (US)
13.5.2. Novartis United States
13.5.3. AbbVie Inc.
13.5.4. Myriad Genetics
13.5.5. NeoGenomics Laboratories
13.5.6. Intellia Therapeutics (US)
13.5.7. Agilent Technologies, Inc. (US)
13.5.8. Abcam plc.
13.5.9. Bio-Techne. (ExoDx)
13.5.10. Sangamo Therapeutics, Inc. (US)
14. Strategic Recommendations